Keros Therapeutics, Inc. (NASDAQ: KROS) Stock Information | RedChip
Image

ASK REDCHAT® ANYTHING ABOUT KEROS THERAPEUTICS, INC.

Keros Therapeutics, Inc. (NASDAQ: KROS)
Listen to this Section


$11.00
-0.0050 ( -0.23% ) 550.9K

Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.

Market Data


Open $11.00
Previous Close $11.00
Volume 550.9K
Market Cap $445.58M
Day Range $10.97 - $11.25
52 Week Range $9.78 - $73.00
Shares Outstanding 40.51M
Change % -0.23%
Net Change ▼ -0.0050
Insider Ownership -0.06%
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
IPO Year 2020
Country United States
Under Writer IPO Intelligence Only

Insider Ownership Transactions

Total Amount Purchased: -607,600.00

Date Type Amount Purchased Purchaser
2024-06-05 Sale -17600.00 BIENAIME JEAN JACQUES
2024-06-03 Sale -10000.00 Kariv Tomer
2024-06-03 Sale -10000.00 Knowles Julius
2024-06-03 Sale -10000.00 GRAY MARY ANN
2024-06-03 Sale -10000.00 GORDON CARL L
2024-06-03 Sale -10000.00 Farzan Nima
2024-06-03 Sale -10000.00 Nussbaum Ran
2024-06-03 Sale -10000.00 Seth Alpna
2024-02-23 Sale -125000.00 Seehra Jasbir
2024-02-15 Sale -125000.00 Seehra Jasbir

Institutional Ownership

Total Market Value $ 0.00

Symbol Issuer Name Market Value ↓ Share Quantity
No records found.

SEC Fillings


Form Type Description Pages Date
8-k 8K-related 14 Jun 03, 2024
4 Insider transactions 1 Jun 03, 2024
4 Insider transactions 1 Jun 03, 2024
4 Insider transactions 1 Jun 03, 2024
8-k 8K-related 13 May 30, 2024
8-k 8K-related 14 May 28, 2024
8-k 8K-related 14 May 08, 2024
10-q Quarterly Reports 51 May 08, 2024
ars Annual reports 1 Apr 17, 2024
def Proxies and info statements 21 Apr 17, 2024

Latest News


× Before browsing our site, please accept our cookies policy